Monte Rosa Therapeutics (GLUE) Other financing activities (2021 - 2026)

Monte Rosa Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Other financing activities rose 32200.0% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $10.2 million (up 1134.14% YoY), while the FY2025 annual figure was $5.7 million, up 439.4% from the prior year.
• Other financing activities for Q1 2026 stood at $4.5 million, down from $5.4 million in the prior quarter.
• The five-year high for Other financing activities was $49.8 million in Q2 2024, with the low at -$49.3 million in Q3 2024.
• The 5-year median for Other financing activities is $246000.0 (2024), against an average of $810294.1.
• The sharpest annual moves came in 2024 and 2026: Other financing activities tumbled 2979.04% in 2024, then surged 32200.0% in 2026.
• Monte Rosa Therapeutics' Other financing activities stood at $439000.0 in 2022, then tumbled by 96.81% to $14000.0 in 2023, then soared by 2607.14% to $379000.0 in 2024, then surged by 1314.51% to $5.4 million in 2025, then decreased by 15.65% to $4.5 million in 2026.
• Business Quant data shows GLUE's Other financing activities at $4.5 million in Q1 2026, $5.4 million in Q4 2025, and $362000.0 in Q3 2025.